期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 633, 期 1-3, 页码 62-70出版社
ELSEVIER
DOI: 10.1016/j.ejphar.2010.02.003
关键词
Ezetimibe; Pleiotropic effect; Endothelial function; Lipoprotein subfraction; Inflammatory marker; Insulin resistance
Ezetimibe represents a new lipid lowering agent which inhibits cholesterol absorption. It effectively reduces low-density lipoprotein cholesterol when administered either alone or in combination with statins. However, its effect on cardiovascular mortality remains under question since it failed to demonstrate any significant changes in the primary endpoints of the recently published ENHANCE and SEAS studies. A possible explanation for this unsuccessful outcome is that ezetimibe lacks pleiotropic effects. This article aims to review the potential pleiotropic effects of the drug mainly on inflammation markers, lipoprotein subfractions and endothelial function. (C) 2010 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据